

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-77. (Canceled)

78. (Currently amended) A method for identifying an antagonist of MCK-10, comprising: (a) contacting a cell line that expresses either (i) an MCK-10 protein comprising the amino acid sequence of SEQ ID NO. 2, or (ii) a splice variant thereof, with a test compound; ~~and~~ (b) determining whether said test compound inhibits the binding of a ligand to said MCK-10 protein or splice variant thereof, and (c) subsequently determining the activity of said MCK-10 protein or splice variant thereof, wherein a test compound that inhibits binding of a ligand to said MCK-10 protein or splice variant thereof, and thereby reduces or inhibits the activity of the MCK-10 protein or splice variant thereof, is an antagonist of MCK-10.

79. (Previously added) The method of claim 78, wherein said cell line is a genetically engineered cell line.

80. (Previously added) The method of claim 78, wherein said cell line endogenously expresses the MCK-10.

81. (Currently amended) A method for identifying an antagonist of MCK-10, comprising: (a) contacting a cell line that expresses either (i) an MCK-10 protein comprising the amino acid sequence of SEQ ID NO. 2, or (ii) a splice variant thereof, with a test compound; ~~and~~ (b) determining whether said test compound inhibits the binding of a ligand to said MCK-10 protein or splice variant thereof, thereby effecting a cellular change in said cell line; and (c) subsequently determining the activity of said MCK-10 protein or splice variant thereof, wherein a test compound that effects a cellular change in said cell line and reduces or inhibits the activity of the MCK-10 protein or splice variant thereof is an antagonist of MCK-10.

82. (Previously added) A method for identifying a peptide that binds to MCK-10, comprising: (a) contacting an MCK-10 protein comprising the amino acid sequence of SEQ ID NO. 2, or a splice variant thereof, with a random peptide library; (b) isolating a complex comprising an (i) MCK-10 protein, or splice variant thereof, and (ii) a peptide; and (c) determining the sequence of the peptide of said complex.

83. (Currently amended) A method for identifying a compound that modulates ~~affects~~ MCK-10 activity, comprising: (a) contacting a cell line that expresses either (i) an MCK-10 protein comprising the amino acid sequence of SEQ ID NO. 2, or (ii) a splice variant thereof, with a test compound; and (b) determining whether said test compound modulates the activity of said MCK-10 protein or splice variant thereof.

84. (Previously added) The method of claim 83, wherein said test compound inhibits the activity of said MCK-10 protein or splice variant thereof.

85. (Currently amended) A method for identifying an antagonist of MCK-10, comprising: (a) contacting an MCK-10 protein comprising the amino acid sequence of SEQ ID NO. 2, or a splice variant thereof, with a test compound; ~~and~~ (b) determining whether said test compound inhibits the binding of a ligand to said MCK-10 protein or splice variant thereof; and (c) subsequently determining the activity of said MCK-10 protein or splice variant thereof, wherein a test compound that inhibits binding of a ligand to said MCK-10 protein or splice variant thereof, and thereby reduces or inhibits the activity of the MCK-10 protein or splice variant thereof, is an antagonist of MCK-10.

86. (Currently amended) A method for identifying a compound that modulates ~~affects~~ MCK-10 activity, comprising: (a) contacting an MCK-10 protein comprising the amino acid sequence of SEQ ID NO. 2, or a splice variant thereof, with a test compound; and (b) determining whether said test compound modulates the activity of said MCK-10 protein or splice variant thereof.

87. (Previously added) The method of claim 86, wherein said test compound inhibits the activity of said MCK-10 protein or splice variant thereof.